Wayne State University
Neurology Faculty Publications

Department of Neurology

4-1-2015

Molecular Pathways of Chemokine Receptor
Desensitization by IL-16 Pertinent to Multiple
Sclerosis
Dusanka S. Skundric
Wayne State University, skundric@wayne.edu

Recommended Citation
Skundric, DS. Molecular pathways of chemokine receptor desensitization by IL-16 pertinent to multiple sclerosis.
http://nn.neurology.org/content/2/3/e76.short/reply#nnn_el_60 retrieved on 5/19/15 Letter in response to: Spencer CM,
Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients
treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76. doi: 10.1212/NXI.0000000000000076
Available at: http://digitalcommons.wayne.edu/med_neurology/6

This Article is brought to you for free and open access by the Department of Neurology at DigitalCommons@WayneState. It has been accepted for
inclusion in Neurology Faculty Publications by an authorized administrator of DigitalCommons@WayneState.

NOTICE IN COMPLIANCE WITH PUBLISHER POLICY: This is an open access article distributed under the
terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits
downloading and sharing the work provided it is properly cited. The work cannot be changed in any way
or used commercially.

Article:
Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl
fumarate
Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS. Reduction of CD8(+) T
lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol
Neuroinflamm. 2015 Feb 12;2(3):e76. doi: 10.1212/NXI.0000000000000076

Letter in Response to Above Article:
Molecular pathways of chemokine receptor desensitization by IL-16 pertinent to multiple
sclerosis
Dusanka S. Skundric, Assistant Professor
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Multiple sclerosis (MS) is a progressive, autoimmune CD4+ T cell - mediated, inflammatory,
demyelinating disease of central nervous system (CNS). Long-term MS therapy increases risk of
opportunistic viral infections due to non-specific immune down-regulation. The important study from
Spencer at al. revealed distinct changes within lymphocyte and leukocyte subsets in MS patients treated
with dimethyl fumarate (DMF). [1]

An overall reduction in immune cell counts and pronounced down-regulation of CD8+ T cells weaken
innate immune responses to viruses in DMF treated MS patients. Viral infection can trigger autoimmune
responses primary to development or progression of MS. Migration of chemokine receptor expressing
activated autoimmune cells can be potentially controlled by viral chemokines. Crystallography data
revealed interaction between viral vMIP-II and CXCR4. [2] CXCR4 and its endogenous ligand chemokine
CXCL12 are implicated in MS. A CD4+ T cell specific chemotactic factor, cytokine IL-16, by binding to CD4
co-receptor induces receptor desensitization of CXCR4 independent of p56lck enzymatic activity. [3]
Production of IL-16 corresponds to CD4+ T cell inflammation, demyelination, and axonal degeneration in
MS lesions. [4] Multifaceted properties of IL-16 include regulation of autoimmune and viral responses.
[5] I propose use of IL-16 in combination MS therapy to avert complications of immune suppression.
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